Actinogen Medical (ASX:ACW) has announced positive results from its XanaCIDD phase 2a depression trial. Xanamem, the company's drug candidate, demonstrated consistent benefits in reducing depression symptoms across multiple endpoints, suggesting its potential as a novel treatment for Major Depressive Disorder. Shares are trading 104.17 per cent higher 4.9 cents.
Kalina Power (ASX:KPO) signed a non-binding agreement with a US data centre developer to build AI-focused data centres powered by natural gas plants with carbon capture. They aim to finalise a binding agreement with non-dilutive funding for Kalina and long-term power purchase agreements in the coming weeks. Shares are trading 40 per cent higher at 0.7 cents.
Iltani Resources (ASX:ILT) plans to explore its high-grade Antimony Reward deposit in Queensland. Historic drilling results showed promising antimony mineralisation. Antimony is a critical mineral with growing demand due to China's export bans. Shares are trading 28.89 per cent higher at 29 cents.
